Superworth

Precision Biosciences DTIL

Biotechnology, Healthcare
$6.95
−1.56%
Market cap
$191.8M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
4.3×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$45M
growth n/m, growth from a base too small to compare
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−27.1%

Precision Biosciences trades at 4.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $45M over the last twelve months.

Charts

Financials

Income statement for DTIL, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$7M−34%$17.6M+100%$49.9M+152%$576K−96%$638K−91%$29K−100%$18K−100%$13K−98%$34.2M+5261%$10.8M+37272%$0$0
R&D$13.4M−37%$13.3M+21%$17.2M+32%$13.1M−18%$15.9M+19%$13.6M+2%$12.8M−26%$13.4M+2%$14.5M−9%$13.1M−4%$12.4M−3%$12.7M−5%
SG&A$8.5M−15%$8.4M−24%$8.5M−13%$8.8M−9%$9.6M+12%$8.6M+2%$9.1M+7%$7.3M−16%$7.2M−25%$6.8M−21%$6.8M−26%$7.7M+5%
−$14.9M−27%−$4.2M−69%$24.1M−$21.3M+72%−$24.8M+67%−$22.1M+428%−$21.9M−$20.7M−3%$12.5M−$9.1M−59%−$19.2M−12%−$20.4M−1%
Interest expense$579K+19%$574K+10%$560K+1%$256K−56%$392K−32%$354K−38%$358K−36%$362K+41%$348K−11%$311K−12%$300K−16%$307K−15%
Net income−$16.3M−43%$8.6M$32.7M−$16.4M+103%−$17.7M+9%−$20.6M−$23.5M−$21.8M+33%$20.1M−$18.4M−10%−$32.7M+39%−$7.6M−65%
−$4.06−48%$1.70$4.67−$2.25+7%−$2.22−45%−$2.21−$2.13−$1.84−18%$1.06−$0.75−66%−$1.26−41%−$0.28−85%
4M+8%5.1M+37%7M+84%7.3M+90%8M+100%9.3M+84%11M+58%11.8M+62%19.1M+138%24.6M+165%25.9M+134%27.4M+132%

EPS, diluted: 8 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 7 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Precision Biosciences' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
DTILPrecision Biosciences$191.8Mn/m78.9×4.3×n/mn/m
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
ELMDElectromed$223.9M20.4×29.0×3.0×+15%15.3%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
CYHCommunity Health Systems$296.2M8.1×4.5×0.0×−8%0.3%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
VMDViemed Healthcare$359.6M26.2×26.2×1.2×+25%4.8%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
Peer median$224.2M14.0×20.5×1.6×+6%7.3%

More on Precision Biosciences

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .